Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
Date:10/30/2008

G&A expenses in the third quarter of 2008 relative to the second quarter of 2008 is primarily due to lower iloperidone pre-commercial launch expenses. The decrease in G&A expenses in the third quarter of 2008 relative to the third quarter of 2007 is primarily due to lower employee stock-based compensation expense and lower iloperidone pre-commercial launch expenses.

-- Employee stock-based compensation expense recorded in the third quarter of 2008 totaled $3.6 million. Of these non-cash charges, $0.5 million was recorded as R&D expense and $3.1 million was recorded as G&A expense. In the second quarter of 2008 and the third quarter of 2007, total stock-based compensation was $4.0 million and $5.2 million, respectively. The decrease in stock-based compensation in the third quarter of 2008 relative to the second quarter of 2008 and the third quarter of 2007 is primarily due to the lower fair market value of options granted in 2008.

-- Net loss for the third quarter of 2008 was $10.9 million, compared to a net loss of $13.5 million for the second quarter of 2008 and $21.9 million for the third quarter of 2007.

-- Net loss per common share for the third quarter of 2008 was $0.41, compared to $0.51 for the second quarter of 2008 and $0.82 for the third quarter of 2007.

-- Cash and marketable securities decreased by $13.9 million during the third quarter of 2008. Changes included $10.9 million of net losses, decreases in accrued R&D expenses and accounts payable of $5.2 million, net increases in prepaid expenses of $0.9 million, fixed asset purchases of $0.5 million offset by $3.7 million in non-cash depreciation, amortization, and stock-based compensation expenses and net increases in other working capital of $0.1 million.

-- Vanda's cash, cash equivalents, and marketable securities as of September 30, 2008 totaled approximately $51.7 million, compared to approximately $93.2 million as of December 31, 2007.

FINANCIAL GUIDANCE '/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Turing Pharmaceuticals ... Eliseo Oreste Salinas , MD, MSc,  has joined ... Dr. Salinas, who holds a medical ... brings a record of significant accomplishments in the ... Dr. Salinas has played a leadership ...
(Date:6/1/2015)... and YONGIN, South Korea , ... pride that Green Cross Biotherapeutics Inc. (GCBT) kicked off ... located on the Montreal Technoparc,s Saint-Laurent Campus. The CA$315 ... investment projects in Canada in ... the first intravenous immunoglobulin (IVIG) and albumin manufacturing plant ...
(Date:6/1/2015)... GenomeDx Biosciences today announced that ... classified various subtypes of bladder cancer based ... including one type associated with resistance to ... has potential as a tool to predict ... with muscle-invasive bladder cancers (MIBC). The study ...
(Date:6/1/2015)... ON , June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... period ended March 31, 2015.  Biorem,s complete 2015 first quarter financial ... Financial Summary:Three-months ended March 31,(in CDN$,000 except ... , 4,689 , 1,974 Gross profit , ... (318) Net earnings (loss) , 528 , ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3
... Calif., April 16 Cord Blood America, Inc. (OTC ... preservation company ( http://www.cordblood-america.com ) ... cells to families nationwide and internationally, said today that ... business increased 8.7 percent, or $0.3 million, to $3.4 ...
... of drug safety services to the life sciences industry, has appointed Charles ... Saldarini is a proven leader in the field of biopharmaceutical outsourcing services. ... of CEO as he established the company as the leader in contract ... ...
... -- China Sky One,Medical, Inc. ("China Sky One Medical" ... fully integrated pharmaceutical company producing over-the-counter,drugs in the People,s ... a conference call at 10:00 a.m. Eastern Daylight Time ... quarter and fiscal year 2008,financial results. , ...
Cached Biology Technology:Cord Blood America Announces 2008 Financial Results 2Charles Saldarini is New CEO of Sentrx 2Charles Saldarini is New CEO of Sentrx 3China Sky One Medical, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2008 Results 2
(Date:5/11/2015)... May 11, 2015  Through a well-rounded UAS delegation representing ... had a strong showing at AUVSI,s Unmanned 2015 conference last ... Ohio,s UAS industry met with over ... all points along the UAS ecosystem. "Our ... Vice President for Aerospace Rich Knoll . "If you ...
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a developer ... helmet producer, announced today that they will expand their ... world,s first bio-sensing cycling helmet and the first joint ... two new colors in order to give cyclists more ... In addition, LifeBEAM and Lazer announced their plan to ...
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... Western Reserve School of Medicine have discovered a technique ... brain cells destroyed in patients with multiple sclerosis, cerebral ... This discovery appears today in the journal Nature ... production of myelinating cells, which provide a vital sheath ...
... N.J.The State of Spinal Cord Injury: Latest News on ... be held on Wednesday, April 17, 2013, from 4:30 ... Way, West Orange, N.J. This special Grand Rounds is ... System (NNJSCIS) and the Spinal Cord Injury Project of ...
... (Philadelphia, PA) A major factor in the advance of ... that a team of scientists at Temple University School of ... with new medicines. Now, the researchers are one step closer ... key molecule in an unexpected place in heart cells ...
Cached Biology News:Ordinary skin cells morphed into functional brain cells 2The State of Spinal Cord Injury Grand Rounds 2Clues to heart disease in unexpected places, Temple researchers discover 2Clues to heart disease in unexpected places, Temple researchers discover 3
Rabbit polyclonal to MDM2 (phospho S185) ( Abpromise for all tested applications). entrezGeneID: 4193 SwissProtID: Q00987...
Anti-ADAM-12 (Meltrin Alpha); carboxy terminal end; rabbit host...
Chaps Cell Extract Buffer can be used to lyse cells under nondenaturing conditions and is recommendedfor the preparation of cell lysates to be used with our caspase signaling pathway antibodies...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Biology Products: